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Natural products represent one of the most important reservoirs of structural and chemical diversity for the generation of leads
in the drug development process. A growing number of researchers have shown interest in the development of drugs based on
Chinese herbs. In this review, the use and potential of omic technologies as powerful tools in the modernization of traditional
Chinese medicine are discussed. The analytical combination from each omic approach is crucial for understanding the working
mechanisms of cells, tissues, organs, and organisms as well as the mechanisms of disease. Gradually, omic approaches have been
introduced in every stage of the drug development process to generate high-quality Chinese medicine-based drugs. Finally, the
future picture of the use of omic technologies is a promising tool and arena for further improvement in the modernization of
traditional Chinese medicine.
1. Natural Products and Traditional Chinese
Medicine in Drug Discovery
Since ancient times, plants have been an essential element for
the prevention and treatment of a wide variety of diseases.
Historically, natural products represent one of the most
important reservoirs of structural and chemical diversity for
the generation of leads in the drug development process
[1, 2]. The tendency to develop drugs from natural sources
can be clearly observed in a study of the sources of drugs
between 1981 and 2010. The study showed that about 45%
of the approved drugs by the FDA were natural products or
natural products derivatives [3, 4].
In the past years, the use of herbal preparations has
gained attention in European and Asian countries. Only in
Europe, about 100 million people make use of traditional
and complementary medicine. Furthermore, the increasing
popularity of traditional and alternativemedicine is observed
in Africa, Asia, Australia, and North America [5–7]. In
academia and industry, a growing number of researchers have
shown interest in the development of drugs based on Chinese
herbs [2].
Traditional ChineseMedicine (TCM) is a medical system
for the prevention and treatment of diseases that focuses
on the patient rather than the disease when compared to
the Western medicine. The main principle by which TCM
works is the use of herbs for the restoration of the yin-
yang imbalance that results in disease [2]. Despite the
increasing popularity and interest on TCM, researchers face
a challenging task when gathering scientific evidence and
clinical validation of Chinese based herbal remedies. The
main bottlenecks in the study of TCM include quality control,
the identification of cellular targets, mechanism of action,
and clinical validation due to the variability of the individual
herbal ingredients, the complexity of herbal formulations,
and the combined action on different targets (Figure 1) [6, 8].
Novel advanced technologies are needed to improve sep-
arationmethods, quality control, standardization techniques,
screening, the study of the mechanism of action of individual
compounds, and clinical validation assays. In this sense,
the application of omic technologies in TCM research is a
promising approach to assist in the modernization of TCM
and to address the complex challenges encountered in TCM
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Figure 1: Application of omic technologies to tackle the main challenges in TCM research.
research. Therefore, the aim of this review is to give a general
overview of the use of omic technologies as promising and
powerful tools in TCM research.
2. Omic Approaches in TCM Research
The rapidly evolving technology has led to the development
of research tools to assist a more comprehensive study
of biological systems. In TCM, researchers have gradually
introduced the most recent technological advances trying to
overcome the most common bottlenecks in TCM research.
By analyzing the emergence and evolution of the current
technologies, their potential application in TCM research can
be better understood.
A significant breakthrough in technological advances
was the completion of the Human Genome Project which
is considered one of the greatest scientific achievements of
the past century [9]. The genomic revolution in the Human
Genome Project was the platform that contributed to the
development and improvement of technologies for identifica-
tion of drug targets, target validation, and disease etiology
[10, 11]. Some of the technological advances include Sanger
DNA sequencing, nanotechnology, miniaturization and
automation technologies, DNA-based genetic markers, clon-
ing systems, polymerase chain reaction, and genotyping of
single nucleotide polymorphism. The techniques developed
during the Human Genome Project have played an essential
role in the understanding of biological processes [11].
Despite the significant contribution of genomic studies,
the need to bridge the sequence information for the identi-
fication of potential therapeutic targets with the physiology
and pathology of an organism using novel sophisticated
approaches became a clear and pivotal task [10]. One way
to fill the gap between genomic information and biological
processes was the use of combined strategies from several
levels together with analytical technologies and improved
computational power. The integration of technology, bioin-
formatics, and molecular biology approaches at different
organizational levels is comprised in systems biology and
provides a complete picture to understand the molecular
mechanisms [12, 13].
The postgenomic era was a pivotal stage for the emer-
gence of “omic” studies in biological research representing
the beginning of the systems biology era. Data generated by
omic studies are described as the wholeness of living systems
that result in useful information after the application of
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Figure 2: Omic approaches and their area of study in systems biology.
bioinformatic analyses [14]. The organizational levels in sys-
tems biology include genomics, transcriptomics, proteomics,
and metabolomics [12]. Furthermore, new omic concepts
and technologies have been introduced comprising more
specialized areas of study in systems biology [14] (Figure 2).
The analytical combination of information from each
omic approach is crucial for understanding the working
mechanisms of cells, tissues, organs, and organisms as well as
the mechanisms of disease [11, 15]. Visualization and analysis
of combined multiomic data increase, in a large scale, the
comprehensive understanding of biological processes [14].
Therefore, application of omic approaches in TCM represents
powerful tools for the development of high-quality herb-
derived drugs.
2.1. OmicApproaches atDNALevel. Genes and gene products
act as a complex interconnected network in synchrony with
a wide variety molecular system pathways rather than acting
independently. Since the establishment of omics approaches,
omic technologies have been applied in different areas
of biotechnology, drug discovery, and biomedical research
including TCM. However, a close analysis of the omic
research published in the past ten years shows that the use
of omic technologies in TCM has not been fully explored
[16]. Therefore, special attention should be paid to link the
advantages of omic techniques with the complex concerns
encountered in TCM research.
Another omic approach atDNA level is epigenomics. Epi-
genetic studies focus on the reversible heritablemodifications
in gene expression that do not involve any change in the DNA
sequence [14, 17]. As an omic approach, the aim of epige-
nomics is to identify gene alterations through the analysis of
epigenetic changes that take place in the whole genome [14].
Despite promising findings, the application of epigenomics in
TCM needs further exploration [17].
Metagenomic studies involve the analysis of a collection
of genes from the environment that are related to the host
physiology [14]. This approach is of particular interest when
studying the relationship between the gut microflora and the
pathophysiological state of the host and drug metabolism
[18]. So far, the contribution of metagenomics in TCM
research represents a novel and promising area of study that
contributes to the modernization of TCM.
The study of the alterations in gene expression upon
exposure to chemicals to identify potential genetic toxicants
and monitor their cellular mechanisms is the main focus
of toxicogenomics [14, 19]. Toxicogenomics comprises the
dynamics between genes and environmental stress in disease
etiology and development [20].
Pharmacogenomics aims to identify and analyze genes
involved in the response to drugs to assess interindividual
variability and susceptibility to adverse drug reactions [21,
22]. Pharmacogenomics studies provide valuable informa-
tion to determine doses for the effective and safe use of
medications [14]. In the field of TCM research, databases
have been constructed including active compounds found
in Chinese herbs which are categorized using chemical
informatics protocols. Multidisciplinary integration of data
4 Evidence-Based Complementary and Alternative Medicine
generated by other omic approaches provides a wider and
more understanding overview of pharmacogenomics applied
to TCM research.
Herbogenomics, also referred as botanogenomics, is a
novel concept that makes use of genomic and proteomic
comparative analysis for the study of the biological effect
of herbs [23]. This concept has emerged as an attempt to
introduce a more specialized platform particularly focused
on herbal remedies [23, 24].The comparison between treated
and control groups gives an insight into the genome and
proteome alterations that take place upon treatment with
herb-derived compounds or herbal preparations.
2.2. Omic Approach at RNA Level. Transcriptomics com-
prises the study of the complete set of messenger RNA under
specific conditions in any given cell; it is also known as the
study of transcripts [12, 25]. By using genetic association
databases, it is possible to make comparisons between the
gene expression profile under treatment with certain herbal
formulae and the profile of disease state or any known
drug. Such comparisons can be used to predict unknown
physiological effects, unwanted interactions, or side effects
[16]. Nonetheless, more transcriptomic information com-
bined with multiomic technologies should be included in
strategies for modernization of TCM.
2.3. Omic Approaches at Protein Level. The above-mentioned
omic approaches have contributed to the understanding of
biological processes for the evaluation and validation of
TCM. Another promising technology developed that has
strongly emerged as a powerful tool for the assessment of
physiological events is proteomics. Since the introduction of
the term proteomics for the first time 20 years ago, proteomic
technologies have rapidly evolved and being integrated into
several stages in the pharmaceutical research and develop-
ment [26]. Proteomic studies focus on the whole population
of proteins in a specific cell type, tissue, body fluid, or a whole
organism at a given time [14, 27]. The concept of proteomics
can be described from the point of view of TCM in which the
Qi or vital essence is the result of the overall performance of
the proteome [28].
The downstream complexity of mechanisms that lead to a
specific biological effect is not directly related to the number
of genes. Instead, other gene expression mechanisms such
as posttranslational modifications and alternative splicing
play an important role in protein variation. It has been
estimated that about 35% of human genes undergo alternative
splicing which means that the traditional one gene one
protein hypothesis should be adjusted to a one gene-many
protein model [13, 25]. As a consequence, proteomics has a
particularly important impact on the discovery of novel drug
targets [26].
Phosphorylation is considerably the most commonly
found posttranslational modification in proteins accounting
for about 17,500 phosphorylated gene products in humans
[29]. Phosphorylation of proteins plays a pivotal role in
crucial cell mechanisms including gene expression, cell sig-
naling, metabolism, cell growth, and cell differentiation [14].
In addition, alterations in protein phosphorylation have been
directly involved in disease etiology and progression, but
only a small number of proteins, about 350 proteins, have
been experimentally validated [29]. Despite the enormous
potential of phosphoproteomics technologies, the difficulties
encountered in the development of sophisticated, sensitive,
and reliable phosphoproteomic methods may contribute to
the slow introduction of these techniques in TCM studies.
Similarly, as phosphoproteomics, glycoproteomics com-
prises the study of proteinswith another important posttrans-
lational modification in cell processes, namely, glycosylation.
Glycosylation of proteins occurs in about 25% of the human
proteins and nearly 4,500 proteins have being detected
to undergo glycosylation [29]. However, some estimations
reveal that glycosylation may occur in about 50% of all
human proteins. Glycosylated proteins participate in cellular
functions including cell adhesion, cell immunity, protein
translation, and protein degradation among other cellular
functions [14]. Although glycoproteomic technologies are
currently available and have shown great potential in drug
discovery and drug development, the application of these
technologies in the development of high-quality TCM-
derived drugs needs to be explored.
Another omic approach that focuses on the proteome is
toxicoproteomics which is used to evaluate the effect of the
exposure to toxic agents in cells and tissues at qualitative and
quantitative level. The proteome profiling upon xenobiotic
exposure allows prediction of toxic responses to herbal
components [30].
Chemoproteomics applies function-based proteomics to
study the protein structure and their interaction with chem-
icals. The proteins subjected to chemoproteomic studies
require carefully optimized conditions to conserve protein
structure, posttranslational modifications, and even inter-
actions with regulatory proteins [14, 31]. Chemoproteomic
approaches can be categorized as global and targeted chemo-
proteomic strategies. The global chemoproteomics approach
focuses on the cellular response, namely, protein expression
or any specific posttranslational modification, upon treat-
ment with a compound of interest [31]. At the end of the ana-
lytical process, bioinformatic tools are applied to characterize
protein structure and function [14].
Immunomics focus on the regulatory mechanisms of
the immune system on pathogens from antigen recognition
to the immune response caused by the antigens presented
to the immune machinery of the host [14, 32]. Although
the immunomodulatory effects of several Chinese herbs are
well known and documented, the use of modern technology
to assess the close interactions and molecular mechanisms
triggered by TCMs using immunomics is still in a very early
stage [33].
Asmentioned above, the use ofmultiple omic approaches
allows a broader andmore detailed understanding of biologi-
cal phenomena from different points of view.The complexity
and a large amount of data generated by each individual omic
approach have led to the emergence of a new omic tool to
combine, analyze, and interpret multiomic data.The result of
the analytical combination of the enormous amount of data
generated by different omic approaches is called integrome
and it is the main focus on interactomics [34]. Interaction
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networks can be constructed using bioinformatic tools in
interactomic studies to track changes in the traits of networks.
The main application of interactomic studies so far has been
in drug discovery [14].
2.4. Omic Approaches atMetabolite Level. Metabolomic stud-
ies include the qualitative and quantitative analysis of a large
number of metabolites and their dynamics in a given biolog-
ical system [12, 35]. The aim of metabolomics is the measure-
ment of the global, dynamic, and downstream homeostatic
effect in biochemical pathways caused by specific stimuli
[16]. The stimuli that induce changes in the metabolic profile
can be categorized as internal factors such as genetic mod-
ifications, as well as external factors such as environmental
and pharmaceutically induced effects [12]. The metabolic
profiling can also provide important information about the
pathophysiological, pharmacodynamics, and pharmacoki-
netic condition [16]. Any change in the living system in terms
of physiology, pathology, or any other disturbance will lead to
changes in the metabolome [14].
The metabolic state of an individual is influenced by
environmental, genetic, and gut microbiome factors. Com-
parative studies of themetabolic profiles before and after drug
exposure provide valuable information about the treatment
outcome and the effect of drugs on metabolism. Pharma-
cometabolomics is currently applied in pharmacology, drug
discovery, and development and personalized therapy [36].
In recent years, pharmacometabolomic studies have been
widely applied in TCM studies contributing to a better
understanding of the metabolic profile-TCM effect.
The omic discipline that combines metabolomics and
toxicology in comparative analyses of endogenous metabo-
lite profiles in a normal state and during and after drug
treatment is toxicometabolomics [37]. Since safety is one
of the main concerns in TCM research, metabolomics
and toxicometabolomics are very useful tools to assess the
toxicological processes in TCMs [14]. For instance, several
studies investigated the mechanistic basis of aristolochic acid
nephrotoxicity using 1H-NMR spectroscopy, GC-MS, and
LC-MS [38–41]. In this regard, toxicometabolomic approach
uncovered that aristolochic induced nephrotoxicity in aris-
tolochic acid treated ratsmay be arising fromdecreased levels
of prostaglandins resulting in a reversible vasoconstrictive
state and kidney lesions [38–41]. A similar investigation was
also conducted to investigate the nephrotoxic effect of long-
term usage of ricin-based products. Ricin is a water-soluble
glycoprotein based key toxin of Ricinus communis (also
known as castor-oil plant). Long-term treatment with ricin
was shown to induce perturbations in multiple metabolic
pathways including amino-acid metabolism and oxidative
stress which partly explains the observed nephrotoxicity
[42]. Furthermore, a GC-MS study investigated hepatotoxic
effects of triptolide (the active anti-inflammatory ingredient
of Tripterygium wilfordii) and discovered changes in ß-
oxidation pathway [43]. Together, these toxicometabolomic
studies demonstrated the potential of metabolomic technolo-
gies for understanding TCM-based toxicity.
Lipids play essential roles in biological processes from
energy reservoirs and structural cellular components to
elements in cell-signaling pathways [44]. Studies on the
lipidome, the lipid profile in biological systems, have shown
that disturbances in lipidmetabolites are closely related to the
development of diseases such as obesity, Alzheimer’s disease,
diabetes, and some infectious diseases [14, 45]. However,
analytical challenges have been encountered in lipidomic
studies due to the chemically diverse structure of lipids
in complex biological mixtures. Therefore, the technologies
used in lipidomic studies require constant improvement to
provide more sensitive and accurate analysis of the lipid
profile in biological samples.
The phytochemome comprises the group of compounds
present in plants such as alkaloids, polyphenols, terpenes,
sulfides, thiols, plant peptides, and their metabolites. Phy-
tochemomics focuses on the intracellular and extracellular
study at different molecular levels, the chemical structure,
and mechanism of action of the phytochemome [46]. Phy-
tochemomic analytical approaches use the same methods
that are used in metabolomics studies. The main difference
betweenmetabolomics and phytochemomics is that the latter
only focuses on the chemical analysis of compound present
in plants. The phytochemomic concept has not been widely
used. Therefore, it is more common to find in the literature
the term metabolomics when studying phytochemicals.
The focus of chinmedomics is to investigate the biological
action, synergistic effect, and metabolic profile of Chinese
formulae. Chinmedomics has shown great potential when
studying TCM since it introduces the holistic concept of
TCM combined with the most sophisticated analytical tools
[47, 48].
The technologically driven advances in chinmedomics
have been used to address the efficacy and safety concerns
in TCM research [47, 49]. To ensure the therapeutic effect of
TCM treatment, the serum pharmacochemistry analysis is
assessed to collect information about the mechanism of
action, the interaction among the components of the formu-
lae, and the assessment of the relationship between syndrome
and TCM.
2.5. Omic Approaches at Ion Level. Metallomics is defined
as the comprehensive quantitative and qualitative analysis of
an entire set of metals and metalloid species within a cell,
tissue, or the whole organisms [50]. Since it is well known
that a lot of proteins require the presence of metals such
as copper, ion, zinc, and molybdenum as cofactors to exert
their biological actions, metallomics significantly contributes
to studying protein function [14].
Crucial physiological processes such as cellular signaling,
metabolism, enzymatic activity, and transmembrane trans-
port involve the action of ions [14]. The ionome, a concept
introduced 10 years ago that refers to the study of the mineral
nutrients and trace elements in a cell or organism, is the focus
of ionomic studies [51, 52]. The quantitative measurement of
changes in the mineral composition of a specific tissue or
organism as a response to internal or external stimuli, namely,
normal or pathological physiological processes, drug effect,
or genetic modifications, is carried out in ionomic studies
[53].
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2.6. Omic Approaches at Cellular Level. The phenotype is the
whole set of physical and biochemical characteristics of a
living organism as a result of interaction with genetic and
environmental factors [14, 54]. In the disease state, the disease
manifestation, progression, severity of the symptomatology,
and response to therapy are closely related to the genetic
component of the organism and all together defines the
disease phenotype [54].
Phenome is the whole set of expressed traits in a defined
population associated with the influence of genetic of envi-
ronmental factors [14, 55]. Phenomics focuses on the under-
standing and monitoring of the changes in the phenome as a
result of environmental and genetic factors [14]. By studying
the phenotype, the biological processes that occur as a result
of genetic and environmental influences can be reflected in
the genomic architecture [55]. Phenomic studies are difficult
to carry out regarding TCM since it is complex to identify
the compounds responsible for the therapeutic effect due to
the rich chemical content of herbal remedies. However, the
integration, analysis, and understanding of phenomic data
applied to TCM studies represent a valuable tool in TCM
research.
The study of the phenotype at a cellular level for the
understanding of molecular disease networks is the focus
of cytomics. In order to gain more understanding of the
molecular processes at a cellular level, the human cytome
project was conceived [56]. However, the application of these
technologies in TCM research is quite limited.
As discussed above, the diversity of omic approaches
provides a wide variety of technological tools that are applied
to TCM research. In addition, the potential applications of
some omic technologies in TCM research should be further
explored. In Table 1, a summary of all the omic technologies
discussed above and their application in different areas of
the drug discovery and drug development process in TCM
research is presented.
Omic technologies can be applied to the study of a
wide variety of diseases as shown in Table 2. Therefore, the
potential use of omic technologies in TCM research has a
wide scope of application.
3. Quality Control and Safety of
TCM Using Omic Technologies
A critical concern in TCM research is to ensure quality,
safety, and efficacy to meet the quality standard requirements
[93]. In the regulatory context, the assessment of herbal
medicinal products has been included in protocols and
guidelines developed by regulatory authorities and monitor-
ing agencies such as the European Medicines Agency, the
European Food Safety Authority, the Chinese State Food
and Drug Administration, the Herbal Medicinal Product
Committee (European scientific committee), and the World
Health Organization. The latest has published a series of test
methods for identification, purity, and content assessment in
the quality control Methods for Medicinal plant materials
[94–97]. The European Medicines Agency has developed
guidelines including the guideline on good agricultural and
collection practice for starting materials of herbal origin,
guideline on quality of herbal medicinal products/traditional
herbal medicinal products, guideline on the quality of com-
bination herbal medicinal products/traditional herbal prod-
ucts, and the guideline on specifications: test procedures and
acceptance criteria for herbal substances, herbal preparations,
and herbal medicinal products/traditional herbal medicinal
products [98]. In order to meet the criteria established
by local and international regulatory agencies for quality
assurance, safety, and efficacy in traditional medicine, omic
technologies have played a crucial role in facilitating the
sensitive and efficient evaluation of herbal-based medicines.
In TCM, the diversity and number of components
responsible for the biological activitymake the analytical pro-
cedure a challenging task. However, emerging technologies
and improved methods have contributed to facilitating the
quality control of TCMs. Some of the technologies applied in
the characterization ofmetabolites for quality control include
NMR-basedmetabolic fingerprinting, capillary electrophore-
sis,HPLC, gas chromatography,HPLC-PDA-ESI/MS,HPLC-
DAD-ESI/MS, GC/MS, GCxGC-qMS, TOF/MS, GCxGC-
TOF/MS, MALDI-TOF/MS, HLPC/UV, TLC, ultra-TLC,
UPLC, UPLC-Q/TOF-MS, IT-TOF-MS, capillary zone elec-
trophoresis (CZE), capillary electrochromatography (CEC),
pressurized CEC, micellar electrokinetic chromatography,
turbulent flow chromatography (TFC), and HPLC/ESI/MS
[93, 99–101]. Some of the above-mentioned technologies
including MALDI-TOF-MS and UPLC-Q/TPG/MS have
been adapted to high-throughput settings to support a simple,
quick, sensitive, and cost-effective analysis of TCMs [80,
100, 102]. More recently, technology such as miniaturized
and integrated microchips, that is, as Herbochip, DNA
chip, protein chip, and DNA chip, have been developed to
be applied in high-throughput screening of active ingre-
dients [93]. Therefore, DNA barcoding technologies have
also shown to facilitate the standardization, identification,
and quality control of herb-based medicines [103]. 1H NMR
spectroscopy is an analytical tool that allows the detection of
proton-bearing compounds without making any distinction
based on the chemical compound class. This technique is
used to identify and quantify metabolites in a mixture in
a one-step process which facilitates the analysis in high-
throughput settings [104, 105] and is a powerful tool in
the quality control of herbal remedies. For example, 1H
NMR was used to determine the metabolic profile of the
Chinese formula Danggui Buxue Tang traditionally used in
the treatment of menopausal symptoms. The analysis of the
1H NMR spectra of the herbal formula revealed a distinctive
metabolic profile of the decoction when compared to the
individual components of the formula which provides pivotal
information for the standardization and quality control of the
herbal remedy [105].UPLC-MS/MS is beingwidely employed
for the analysis of samples of complex composition since
it provides high resolution for the detection of compounds
present in herbal mixtures without the need for pure stan-
dards [106].
The metabolite characterization is not only useful for as-
sessment of efficacy and safety by determination of the com-
pounds responsible for the biological activity or side effects,
but also it is essential for the standardization during the
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Table 1: Omic technologies and their areas of application in TCM research.
Omic approach Area of application Ref.
Genomics
Drug target identification
Genetic disease markers
Genome manipulation for target validation
[57–59]
Epigenomics
Study of epigenetic mechanisms of
phytochemicals in the regulation of gene
expression
[17]
Metagenomics
Study of the relationship between the gut
microflora and the pathophysiological state of the
host and drug metabolism
[18]
Toxicogenomics
Mechanism of toxicity (chronic, carcinogenic
effect, and secondary effects of drugs)
Biomarkers of toxicity and disease biomarkers
Gene expression profiling of contaminants of
herbal remedies for quality control
Detection of toxic adulterants in herbal
preparations
Screening tests for prediction of toxicity of herbs
in the drug development process
[14, 20, 21]
Pharmacogenomics
Candidate genes with potential relevance in the
efficacy and safety profile of TCMs
Drug targets
Identification of active compounds linking gene
and disease information
[60]
Herbonomics Mechanism of action of herbal componentsToxicity assessment of herbal remedies [23, 24]
Transcriptomics Prediction of therapeutic potential and safety [16]
Proteomics
Therapeutic targets
Exploration of pharmacological effect and
mechanism of multitarget regulatory actions
Quality control and toxicological profile of herbal
remedies
Disease diagnosis
Biomarkers and monitoring of disease progression
[15, 16, 61, 62]
Phosphoproteomics
Study of disease pathogenesis
Disease biomarkers
Drug targets
[14, 63]
Glycoproteomics
Identification of aberrant proteins linked to
pathophysiological processes
Diagnosis biomarkers
Mechanism of disease
Drug targets
[14]
Toxicoproteomics
Detection of biomarkers in response to xenobiotic
exposure
Prediction of toxic response to herbal components
[30]
Chemoproteomics Mechanism of diseaseMechanism of action of compounds of interest [14]
Immunomics
Drug target
Biomarker identification
Study of immunomodulatory effect of herbs
[14, 62]
Interactomics
Drug discovery
Building interaction networks among interacting
molecules
[14, 29]
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Table 1: Continued.
Omic approach Area of application Ref.
Metabolomics
Pharmacokinetics
Pharmacodynamics
Toxicology
Disease diagnosis
Molecular pathology
Botanic identification
Standardization of herbal remedies
Quality control
Elucidation of toxicological profile of herbal
preparations
[64]
Toxicometabolomics
Toxicity related biomarkers
Molecular pathways involved in toxicological
responses to botanicals
[14]
Lipidomics
Mechanism of disease
Drug target discovery
Disease biomarkers
[14, 33, 45]
Phytochemomics
Mechanism of action of herbal compounds
Quality control of herbs
Production of herb-based medicinal products
Toxicity assessment
[34]
Pharmacometabolomics
Study of phenotype signatures by mapping key
pathways of the metabolic drug effects
Pharmacology
Drug discovery and drug development
Personalized medicine
[63]
Chinmedomics
Mechanism of action and metabolic profile of
Chinese formulae
Efficacy and safety of TCMs
Disease biomarkers
[35–37]
Metallomics
Functional study of metal/metalloid-containing
molecules and metabolites (i.e., genes,
polysaccharides, and proteins)
Mechanism of action of herbs
Disease biomarkers
Toxicological profile
Quality control
[14, 45, 46, 65]
Ionomics
Mechanism of disease
Mechanism of action
Disease biomarkers
Toxicological profile
Quality control
[50, 51]
Phenomics
Disease biomarkers
Biomarkers of survival
Therapeutic targets
[66]
Cytomics
Disease biomarkers
Drug targets
Target validation
Personalized medicine
Drug development
Pharmacology
Toxicology
[14, 54, 67]
manufacturing process. Differences in quantity and quality of
compounds in TCMs can be due to factors such as the plant
of the plant used, storage conditions, agricultural practices
(growth conditions, geographic area, and time of harvest,
among others), extraction, and preparation methods [15, 35].
Those factors can contribute to the variability in content and
quantity of compounds between batches that could affect
the pharmacological activity [107]. Therefore, metabolome
characterization using the previously mentioned techniques
is essential to ensure the development of high-quality TCMs.
Although important technological advances for the anal-
ysis of TCMs have been developed and applied, some
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Table 2: Examples of application of omic approaches in TCM research per area of study in systems biology.
Level in system
biology Omic approach Disease/health condition Results Ref.
DNA
Genomics Cancer
The different signaling pathways affected by the
compound Kushen injection, a Chinese formula used
for the treatment of different types of cancer, that
contribute to its antitumor activity were identified
including cell proliferation and apoptosis
[68]
Epigenomics Cancer
Gene expression modulatory pathways were elucidated
in cancer models of naturally occurring compounds
such as curcumin isolated from turmeric,
epigallocatechin-3-gallate which is a component of
green tea, genistein isolated from soy, isothiocyanates
present in broccoli, sprouts, and wasabi, lycopene
which is found in tomatoes, and resveratrol present in
grapes, wines, and eucalyptus
[17]
Metagenomics Gut microfloradisturbances
The Chinese formula containing Radix ginseng,
Rhizoma atractylodis macrocephalae, Poria and Radix
glycyrrhizae traditionally used in the treatment of
spleen deficiency showed restoring effects of the gut
ecosystem by modulation of the gut microflora
composition and structure of the intestinal mucosa
[18]
RNA Transcriptomics Liver diseases
Using microarray analysis, it was observed that the
components of the three yellows heart-draining
decoction (San-Huang-Xie-Xin-Tang) exert their liver
protective activity by acting on the antiproliferation
activity modulated by P53 and DNA damage signaling
cascade
[69]
Protein Proteomics Leukemia
The Chinese medicine Patrinia heterophylla, used as an
antitumor herb, affected the regulation of proteins
involved in energy metabolism, oxidative stress,
apoptosis, signal transduction, differential induction,
and protein biosynthesis which give insights into the
antitumor mechanism of action of this herb on
leukemia K562 cells
[70]
Metabolite
Metabolomics Diabetes type 2
Berberine, a compound isolated from the Chinese herb
Coptis chinensis, showed to downregulate high levels of
13 free fatty acids in patients with diabetes type 2 and
dyslipidemia. A better understanding of the signaling
pathways involved in the mechanism of action of
berberine including fatty acid, insulin resistance, and
glucose pathways was elucidated using metabolomic
analysis
[70]
Toxicometabolomics
Nephrotoxicity induced
by aristolochic acid
(compound widely
present in botanicals)
The mechanism of toxicity of aristolochic acid was
elucidated and it involved direct cytotoxic effect and
inhibition of the enzyme phospholipase A2 which renal
function leading to renal failure
[39]
Lipidomics Hyperlipidemia
Poria cocos, a medicinal fungus used in TCM, induced
positive changes in the fatty acid and sterol profile in an
animal model for hyperlipidemia. Also, the signaling
pathways affected by Poria cocos were identified using
lipidomic analysis
[71]
Phytochemomics Cancer
The antioxidant capacity of 7S and its deglycosylated
form D7S soy protein was evaluated. Both peptides
showed antioxidant activity against free radicals and
showed the effect on proliferation, oxidative status, and
differentiation of H-Caco-2 cells
[72]
Chinmedomics Liver disorders
The Chinese formulae Liu Wei Di Huang Wan
improved the restoration of the metabolic profile that
was disturbed as a result of inflammation processes
[73]
10 Evidence-Based Complementary and Alternative Medicine
challenges are still of significant concern. Frequently, some of
the components responsible for the therapeutic or toxic effect
in TCM have not been fully characterized which hampers
the analytical process [102, 108]. Another limitation in quality
control of herbal preparations is the lack of standards for
the assessment of markers. However, alternative analytical
methods such as quantitative analysis of multicomponent by
a single marker (QAMS) have shown to be effective for the
simultaneous analysis of multiple compounds [102].
In conclusion, the use of omic technologies has enor-
mously contributed to improving the cost effectiveness, sen-
sitivity, and reliability of analytical methods in the quality
control process of TCM. Several analytical techniques are
being introduced in quality control of herbal preparations at
all stages of the production process. The need to have one
optimized analytical procedure for one specific herbal prepa-
ration slows down the development of analytical protocols for
TCMwhen compared to the analytical procedures ofWestern
medicine. More extensive and oriented work is needed to
overcome the issues encountered and to adopt the newest
technological advances in TCM research. However, the intro-
duction of existing technologies and the fast development
of emerging omic tools provide a wide variety of analytical
platforms and promising future to assist in the quality control
of TCM.
4. Omic Technologies in the Study of
Potential Therapeutic Targets
The study of therapeutic targets in TCM is a complex and
challenging task. It requires the use of multiple method-
ologies combined to construct disease maps from different
perspectives since the effect of TCMs is the final result of
the effect on multiple targets. From the genomic point of
view, about 30–40 thousand genes encode a larger number
of proteins that represent potential drug targets for human
diseases [14]. In this arena, omic technologies provide a wide
variety of tools for the study of disease mechanisms and
potential therapeutic targets.
As mentioned above, genomic technologies were the first
methods to be applied in target discovery in combination
with transcriptomics.Microarray analysis andmRNAexpres-
sion profiles used to compare the normal state, disease related
genes, or gene expression under treatment conditions have
shown promising results for target validation. However, the
gene expression profiles might not be directly correlated with
the late functional biological state [14]. Therefore, limitations
of genomic studies in target discovery and disease mecha-
nisms should be addressed by combining the information
collected with the use of other omic approaches such as
proteomics.
The use of proteomic and metabolomic approaches
applied to TCM research has increased since 2006. On the
other hand, genomics and transcriptomics have not been
widely used in TCM research when compared to proteomics
andmetabolomics as shown in observations made until 2012.
Therefore, there is a clear need to explore genomic and
transcriptomic technologies applied to TCM research [109].
Proteomic studies have contributed to the identification
of potential drug targets not only by comparing the proteome
profiles but also by using protein-drug or protein-protein
interaction information [14]. In vitro and in vivo comparative
proteomic studies using TCMs allow the identification of
proteins that are present in the disease state when compared
to the proteome of the normal state and those proteins
can be considered as potential drug targets. After protein
identification, the potential targets should be properly val-
idated to ensure their involvement in the therapeutic effect
of the compound or group of compounds studied. In TCM,
identification of drug targets is essential for approval of TCM
base drugs [110].
A close analysis of themethods used in proteomics for the
study of the mechanism of disease has highlighted the pros
and cons of such methods. For instance, a limitation being
pointed out is the use of gel-based proteomics. Gel-based
separation techniques can lead to partial peptide recovery
from the gel which requires the use of several extraction
steps to increase the peptide yield. However, the multistep
methodologies are time-consuming compared to gel-free
proteomic techniques. It has also been observed that the
resolution of 1D gel systems is not good enough to analyze
complex biological samples [111]. Furthermore, 2D gels have
been a key method in comparative proteomic since their
introduction in the mid-70s [61]. 2D gel technologies have
partially overcome the problems encountered in the use of
1D gels; however, the poor resolution when high abundant
proteins are present in the sample represents another issue
in gel-basedmethods. In addition, gel-based technologies are
time-consuming compared to other separationmethods such
as chromatographic techniques. In order to overcome the
main problems observed in gel-based separation techniques,
gel-free proteomics coupledwithMShave shown to be amore
efficient option in proteomic studies [111].
Proteomic studies can be combinedwith virtual screening
technologies to predict binding profiles of the TCM com-
ponents with potential target proteins and to build protein-
protein interaction maps to track the signaling pathways
involved in the biological effects. Furthermore, the com-
bined data from comparative proteomics, protein-drug, and
protein-protein interaction provide useful information to
support the process for candidate drug targets [14]. Important
advances in MS techniques have been a key element in the
study of the molecular targets of natural products [112].
Particularly, MS techniques namely MALDI-MS and ESI-
MS/MS have been widely applied in target discovery studies.
In natural product research, MS methods coupled to sepa-
ration techniques such as affinity chromatography, includ-
ing small molecule-immobilized chromatography, biotin-
streptavidin affinity chromatography, and photoaffinity label-
ing, have shown to be a powerful combination for target
identification [112].
The study of posttranslational modifications (PTMs) in
proteomics has enormously contributed to the understanding
of molecular mechanisms in biological systems particularly
for the identification of potential drug targets. The study
of PTMs in biological systems is a challenging task due
to the high diversity of PTMs. About 300 different types
Evidence-Based Complementary and Alternative Medicine 11
of PTMs have been identified using the most sophisticated
analytical technologies [113]. New analytical platforms for
the study of PTMs include PTM peptides enrichment steps
after protein extraction and digestion that are followed by
multidimensional analyses such as LC-MS/MS [113, 114].
Chromatographic-based methods are also being used in
PTM studies including hydrophilic interaction chromatog-
raphy (HILIC), chemical derivatization methods, enzymatic
labeling approaches, and immunoaffinity chromatography
methods for the study of glycopeptides [113]. Other chro-
matographic techniques used include the metal oxide affinity
chromatography (MOAC) and immobilizedmetal ion affinity
chromatography (IMAC) which are the most popular meth-
ods for the study of phosphoproteins [113, 115]. Other types
of PTMs such as ubiquitination are studied using antibodies
for enrichment purposes combined with chromatographic
techniques coupled withMS.MS/MS technologies combined
with enrichment methods, such as acetyl-lysine antibodies,
are used for the analysis of protein acetylation [113, 114].
Finally, protein methylation can be assessed by LC-MS/MS,
SILAC-MS combined with enrichment techniques such as
ion exchange chromatography, HILIC, and isoelectric focus-
ing [113]. The information obtained from the study of PTMs
using MS technology has contributed to the understanding
of the signaling networks involved in disease development
and drug activity representing one of the key approaches to
generate information at a protein level for drug development
purposes.Therefore, it is essential to apply themost advanced
methods developed in TCM to contribute to a more efficient,
sensitive, and time effective evaluation of TCMs.
Nowadays, proteomics technologies comprise a wide
variety of high-throughput methods to study complex sys-
tems. A large amount of proteomic data generated can be
analyzed using open source or commercial bioinformat-
ics. Nevertheless, new bioanalytical approaches need to be
developed to manage the enormous amount of proteomic
data to improve the handling, analysis, and visualization of
proteome information [62]. In TCM research, the use of the
most recent analytical tools is growing slowly. On the other
hand, the evolution of the omic technologies and the history
of the implementation of omic technologies in TCM have
shown that great efforts are being made to introduce those
technologies in TCM research.
The comparison of the abnormalities in the metabolome
to the normal stage provides an insight into the pathways
affected at several disease stages, and it is known as compara-
tive metabolomics [116]. For instance, in vitro, in vivo, and
clinical studies have been carried out using MS and NMR
technologies for the assessment of the metabolome in tumor
diagnosis and evaluation of prognosis and to investigate the
effect of the treatment [116]. Comparative omic approaches
are useful tools that provide information about the disease
state to identify the genes/proteins/metabolites involved in
disease development compared to normal states [14]. A
general overview of the application of omic technologies in
differential or comparative studies indicated that coronary
heart disease, chronic liver disease, hypertension, chronic
kidney disease, hyperlipidemia and atherosclerosis, chronic
stomach disease, and diabetes mellitus are the most common
disorders studied in clinical TCM using omic technologies
[109].
Furthermore, metabolomic studies have been shown to
be helpful in the detection of response-to-treatment biomark-
ers which can be used for the development of new drugs [116].
Metabolic and inflammatory disorders are good examples
in which metabolome profiling can assist in the identifica-
tion of potential drug targets and disease biomarkers [14,
116]. The study of disease biomarkers provides information
about diagnosis and disease development [117]. Recently, a
proteomic technology that has been used in the identifi-
cation of disease biomarkers is UPLC-MSE. This approach
involves the use of parallel alternating scans to generate ion
information using low collision energy or to generate a full
scan mass fragment, precursor ion, and neutral ion infor-
mation by high collision energy. The information obtained
by MSE has been shown to provide similar data to the
data obtained by conventional MS/MS analysis. However,
UPLC-MSE technology has the advantage of allowing the
characterization of unknown biomarkers in an untargeted
context [118]. For example, UPLC-MSE was used to study
the metabonomic profile of chronic kidney disease induced
by adenine excess and the protective effects of the TCM
Poria cocos [119]. This metabonomic approach allowed the
identification of disease biomarkers that can be also used
to explain the mechanism of action of Poria cocos [119]. In
other studies, the protective effect of rhubarb and ergone
against chronic kidney disease was evaluated using UPLC-
QTOF/HDMS which provided valuable information about
the pathogenesis of chronic kidney disease, identification of
bioactive fractions, and the mechanism of action of both
herbal mixtures [120, 121]. Another analytical tool is GC-MS
which is considered a basic analytical tool in metabolomic
studies together with NMR and LC-MS [122]. An example
of the application of GC-MS in TCM research is a study in
which a metabolomic profiling of depressed patients treated
with Xiaoyaosan, a Chinese formula used for the treatment
of depression and schizophrenia, was determined [122]. The
metabolic profile obtained by GC-MS in this study allowed
the monitoring of changes in the metabolome present in
the urine of patients receiving Xiaoyasan treatment which
provided more information about its regulatory effect of
neurotransmitter metabolism and its beneficial effects on
depression [122].
In high-throughput settings, metabolomics technologies
are used not only for the identification of biomarkers but
also for understanding the progression and the metabolome
variation in the different disease stages which contributed
to a better understanding of the pathology picture [116]. In
addition, metabolomic profiling is a useful tool for the diag-
nosis and study of the pathological mechanisms. Nowadays,
metabolomics approaches are being explored and introduced
in the development of TCMs [14].
Methods such as NMR-based metabolite profiling,
HPLC, GC-MS, GCxGC-TOF-MS, MALDI-TOF-MS, and
CE-MS are metabolomic tools that can be used for the
simultaneous analysis of 1000 compounds. Such technologies
have shown to be fast, efficient, and sensitive for the detection
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of low abundance metabolites. In terms of bioinformatics
analysis, great efforts are being made to improve the cur-
rent tools in order to integrate the omic information and
generate more reliable and complete bioinformatics tools. An
example of such improved bioinformatic options is the In-
tegrated Interactome System which comprises genes, pro-
teins, metabolites, and drugs data [62]. Together with other
bioinformatics tools such as the Human Metabolome Data-
base, BioMagResBank, the Madison Consortium Database,
MassBank, and the Golm Metabolome Database, metabo-
lomics studies significantly contribute to picture detailed
understanding of disease mechanisms and the identification
of drug targets [116].
Metabolomics profiling can assist in the identification
of early biomarkers of disease which is beneficial to detect
early pathological stages [123]. Early disease biomarker detec-
tion is crucial for the implementation of prevention and
therapeutic schemes in clinics. Therefore, sensitive detection
methods to be developed and applied in TCM research
are highly demanded. Great advances in the application of
metabolomics techniques are taking place and the application
of the most novel methods in TCM is being carried out.
In addition to the omic data generated in TCM studies,
pharmacological evaluation for target validation purposes in
in vitro and in vivo models are needed to complement the
information obtained by omic studies [14].
5. Studying the Mechanism of Action of
TCMs Using Omic Approaches
Chinese formulations comprise a combination of several
herbs. The active compounds in the formulations can act
on specific targets and the biological activity is the result
of combined effects. The final pharmacological action of
the active compounds can be mutual accentuation, mutual
enhancement, mutual suppression, mutual antagonism, or
mutual incompatibility [6]. In order to develop drugs based
on Chinese medicine, the mechanism of action and the
identification of other cellular targets should be properly
established to validate the pharmacological effect and deter-
mine possible side effects [110]. However, the multitarget
actions of a large number of ingredients present in the
formula represent a daunting resource-intensive challenge for
TCM research, especially because most of the cellular targets
and the mechanisms of action are unknown [6, 16, 112, 124].
There is an overlap in themethodologies for identification
of disease mechanisms, biomarkers, drug targets, and the
study of the mechanism of action of TCMs. Some of the
technologies mentioned in the previous section are also
used in the study of the molecular mechanisms in TCMs.
Therefore, themost recent advances in omic technologies that
have being applied in TCM research including some practical
examples and technologies that need further exploration will
be discussed.
Genomic approaches to the study of the mechanism of
action of TCMs have been applied in the past years. A
clear example of the use of recent sophisticated genomic
technologies is the biclustering analysis of gene expression
profiles using DNA microarray technology to identify gene
expression variation.Thedata generated in theDNAmicroar-
ray analysis is used to identify biologically relevant clusters for
gene expression profiles resulting from chemical treatment
to construct connectivitymap (cMap) profiles. Consequently,
the cMAPprofiles are processed by biclustering analysis using
a factor analysis for bicluster acquisition method. The data
generated by the above-mentioned tools combining gene
expression data, statistics, and bioinformatics contributed to
the elucidation of themechanism of action of TCMs and have
shown potential for the analysis of complex herbal formulae
[125].
A combination of technologies such as isoelectric focus-
ing, SDS-PAGE, in-gel digestion,MALDI-TOF-MS, and real-
time PCR have contributed to the identification of proteins
involved in the mechanism of action of curcumin in in
vitro models. Additionally, information about the signaling
pathway in which the differential proteins act can provide
with information about the function and signaling pathway
involved in the mechanism of action [126]. In another study,
a proteomic analysis using 2D gels, in-gel digestion, and
MALDI/TOF/TOF coupled with bioinformatic analysis to
obtain the protein-protein interaction network showed the
identification of proteins and signaling pathways involved
in the effect of curcumin on gastric cancer cells [127]. The
studies mentioned above highlight the enormous amount of
information and understanding of the mechanistic actions
behind the effect of naturally derived compounds which
supports the potential of omic studies in TCM research.
Another detailed study of the use of proteomics to
determine the mechanism of action of TCMs was carried out
by Lao et al., 2014. In this review, the authors summarize
a number of studies based on proteomics in TCM research
carried out in the past 10 years. In this review, it can be
observed that proteomic technologies are being applied in
the study of a wide variety of disorders in in vitro, in vivo,
and in silico studies [128]. Proteomic technologies such as
2D gel electrophoresis, MALDI-TOF-MS combined peptide
mass fingerprint, and the use of Mascot software are used to
elucidate the mechanism of action of triterpenes in leukemia
cells. The study showed the successful identification of pro-
teins associatedwith the antitumormechanismof TCM[129].
The mechanisms of action involved in the hepatoprotective
effects of a TCM were investigated using a combination
of 2D gel electrophoresis, MALDI-TOF/TOF-MS, and the
construction of protein-protein interaction networks using
bioinformatics tools (STRING). Identification of 7 target pro-
teins was possible suggesting the potential of the proteomic
strategy for the elucidation of the mechanism of action of
TCMs [130]. Another recent study has implemented iTRAQ-
based quantitative technology for the identification of disease
biomarkers and the mechanism of action of a Chinese
medicine on a Parkinson’s disease model. In this study, a
detailed protein network map was constructed showing the
molecular pathways involved in the neuroprotective effects of
themedicinal plant studied and the identification of potential
disease biomarkers [74].
When studying the mechanism of action of TCMs, the
use of transcriptomic technologies applied to TCM is pow-
erful tools due to the high sensitivity, accuracy, specificity,
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Table 3: Studies onTCMusing omic technologies (P, proteomics; T, transcriptomics;M,metabolomics; PG; pharmacogenomics;G, genomics;
L, lipidomics).
Disease TCM Omic approach:method Target or signaling pathway Reference
Parkinson’s disease Acanthopanax senticosus P: iTRAQ
Inhibition of the expression of Lewy
bodies; modulation of mitochondrial
energy metabolism, axonal transport,
and protein degradation; suppression
of endoplasmic reticulum stress and
apoptosis; maintenance of centrosome
integrity, iron, and calcium
homeostasis
[74]
Anxiety Radix Rehmanniae Preparata P: 2DGE,MALDI-TOF/MS
Inhibition of MSG-induced
downregulation of 𝛽-synuclein, DJ-1,
peroxiredoxin-2, peroxiredoxin-6,
DDAH-1, and iron-sulfur proteins
[75]
Cerebrovascular disease
Tao Hong Si Wu decoction
(Semen Prunus, Flos
Carthami, Radix Rehmanniae
Preparata, Radix Angelicae
Sinensis, Rhizoma Ligustici
Chuanxiong, and
Radix Paeoniae Rubra)
P: 2DGE,
MALDI-TOF-MS
Regulation of Nrf2-mediated phase II
enzymes [76]
Chronic renal injury Fu-Ling-Pi (Poria cocos) M: UPLCQ-TOF/HSMS/MSE
Regulation of adenine and amino acid
metabolism [77]
Cardiovascular and
kidney disease, cancer Venenum bufonis M: NMR
Cardiac acute toxicity by inhibition of
the Na+/K+ -ATPase pump, activation
of the mitochondrial apoptotic
pathway, increasing the levels of ROS,
disturbance of mitochondrial function,
and induction of apoptosis
[78]
Acute myocardial
ischemia
Danqi Tongmai tablet (Salvia
miltiorrhiza and Panax
notoginseng)
M: LC-LTQ-Orbitrap
MS
Regulation of the tricarboxylic acid
cycle, amino, and nucleotide
metabolism
[79]
Atherosclerosis
Xin-Ke-Shu (Salvia miltiorrhiza,
Pueraria lobate, Panax
notoginseng, Crataegus
pinnatifida, Aucklandia lappa)
M: UPLC-Q-TOF MS
Regulation of fatty acid, beta-oxidation
pathway, sphingolipid metabolism,
glycerophospholipid metabolism and
bile acid biosynthesis, proteolysis,
citrate cycle, lysine and glutathione,
glycerophospholipid, taurine,
hypotaurine, tryptophan, and
arachidonic acid
[80, 81]
Hemolytic and aplastic
anemia
Gui-Xiong (Angelicae Sinensis
Radix and Chuanxiong
Rhizoma)
M:
UHPLC–Q-TOF/MS
Regulation of thiamine and
sphingolipid metabolism [82]
Rheumatoid arthritis Huang-Lian-Jie-Du-Tang M: LC–Q-TOF-MS
Restoration to normal urinary levels of
citric acid, creatine, pantothenic acid,
carnitine, pantothenic acid,
phenylacetylglycine and plasma levels
of uric acid, L-histidine, and
L-phenylalanine
[83]
Systemic lupus
erythematosus
Jieduquyuziyin (Radix
Rehmanniae, Carapax Trionycis,
Herba Artemisiae Annuae,
Rhizoma Cimicifugae foetidae,
Herba Hedyotidis, Radix
Paeoniae Rubra, Herba Centellae
Asiaticae, Semen Coicis, Fructus
Citri Sarcodactylis and Radix
Glycyrrhizae)
M: RRLC-Q-TOF/MS Regulation of unsaturated fatty acidsand phospholipid metabolic pathways [84]
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Table 3: Continued.
Disease TCM Omic approach:method Target or signaling pathway Reference
Gastric cancer Salvia miltiorrhiza
T and P: next
generation
sequencing-based
transcriptomics and
iTRAQ
Inhibition of the metabolism of
glucose in gastric cancer cells and cell
growth
[85]
Cancer Cantharis vesicatoria
PG: PCR array,
microarray-based
transcriptome-wide
mRNA expressions,
and COMPARE
analysis
Induction of apoptosis by regulation of
tumor suppressors p53, p21,
mitochondrial Bax and Bcl-2 proteins,
JAK/STAT pathway, NF-KB, and
oxidative stress that leads to DNA
damage
[86]
Colon, ovarian, and lung
cancer Artemisia annua
PG: microarray-based
transcriptome-wide
expression profiling
and compare analysis
Regulation of TNF, tumor suppressor
p53, c-Myc, and Max-mediated
transcriptional control of gene
expression
[87]
Ischemic stroke
Bu-yang-Huan-wu decoction
(Astragalus membranaceus,
Angelica sinensis, Peonia
lactiflora, Ligusticum chanxiong,
Prunus persica, Carthamus
tinctorius and Pheretima
aspergillum)
G: affymetrix gene
chip array
Downregulation of apoptosis,
inflammation, angiogenesis, and blood
coagulation genes; upregulation of
neurogenesis and nervous system
development genes
[88]
Breast cancer
Si-Wu-Tang extract (Paeoniae,
Angelicae, Chianxiong and
Rehmanniae)
T and G: microarray
transcriptional
profiling
Upregulation of GREB1, EGR3, PGR,
and inhibition of cell growth. [89]
Lipopolysaccharide
induced diseases
Pulsatillae decoction (Radix
Pulsatillae, Rhixoma Coptidis,
Cortex Phallodendri and Cortex
Fraxini)
G: affymetrix chip
Reduction of
lipopolysaccharide-induced damage,
improvement of the physiological and
biochemical responses to overcome
the action of lipopolysaccharides
[90]
Dyslipidemia Review on different TCMs
Several approaches
used such as G, T, and
M
Review on different TCMs [91]
Cancer Panax ginseng
Several approaches
used such as G, P, and
PG
Stimulation of angiogenesis,
modulation of PI3k and AKT
pathways, regulation of cell adhesion,
migration, and cytoskeleton. Effect on
nuclear steroid hormone receptors
[92]
reproducibility, and high-throughput approach [131]. In addi-
tion, microarray technologies for the simultaneous monitor-
ing of a large number of genes represent a very convenient
platform for TCM studies. With the availability of well-
established protocols for sample preparation, RNA isolation,
and amplification, hybridization and data analysis have made
this technology a valuable tool in TCM.Microarray technolo-
gies have been used to elucidate the mechanism of action
of individual compounds or mixture of compounds in TCM
studies. Taken together with databases of gene expression
profiles of TCMs, construction of the drug-gene interaction
signature provides information on the molecular pathways
involved [131].
An example of the use of transcriptomics in the study
of the mechanism of action of TCMs is the study carried
out by Liu et al., 2013. In this study, differential microarray
gene expression analysis in an in vitro platform combined
with pharmacological studies for validation purposes to
elucidate the mechanism of action of the TCM studied. The
data generated were analyzed using the software ArrayTrack,
CLUSTER, and TREEVIEW. The approach used improved
the understanding of the mechanism of action and the
potential use of the TCM in cancer treatment [89]. Addi-
tional examples of studies carried out on TCMs using omic
approaches to elucidate the mechanism of action are shown
in Table 3.
The use of metabolomics technologies provides a deeper
insight into the metabolic changes accompanied by TCM
treatment which enables biomarker identification and eluci-
dation of mode-of-action. Danqi Tongmai tablet was shown
to have a protective effect against acutemyocardial infarction.
Comparison of metabolomic profile of Danqi Tongmai tablet
treated and untreated rats were subjected to pathway analysis
to identify the pathways modified in Danqi Tongmai tablet
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treated rats. Briefly, the knowledge from Kyoto Encyclopedia
of Genes and Genomes (KEGG) was utilized to identify
deregulated pathways. Amore detailed statistical test of path-
way enrichment and comparison of pathway topology were
conducted in MetaboAnalyst [79]. The study demonstrated a
systems-level analysis of metabolic profile for understanding
TCM effector mechanism.
Although omic technologies have being applied in the
study of the molecular mechanism by which TCMs exhibit
their biological effects, more exploration is needed to take
full advantage of the wide range of technologies currently
available.
6. Conclusions
Omic technologies have shown enormous potential in the
modernization of TCM. Gradually, omic approaches have
being introduced in every stage of the development process
to generate high-quality TCMs. The complexity of TCM
in terms of composition and multitarget effects has being
addressed by omic approaches. However, further study and
optimization of the current methodologies are needed to
successfully overcome themost commonbottlenecks in TCM
research. The high chemical and pharmacological diversity
found in TMCs requires the development of a suitable set
of omic technologies established in a strategic manner and
adapted to every specific compound, a group of compounds,
or TCM extracts. Because each plant, formulae, extract, or
group of compounds has different physicochemical nature
and contains different active and toxic compounds as well as
analytical and active biomarkers, each case requires specific
analytical approaches and methodologies that cannot be
applied to another plant, formulae, extract, or group of com-
pounds. The wide variety of technologies available needs to
be further explored and the feasibility of any particular omic
technology or the combination of multiomic approaches
needs to be studied in detail. Therefore, validation of the
strategic omic approaches applied is needed to support their
introduction in guidelines and to allow the development of
standard operation procedures to facilitate reproducibility,
harmonization, and standardization of the protocols used in
the development of TCMs. Emerging novel and sophisticated
omic technologies will require a continuous study and appli-
cation in TCM research. Finally, the future picture of the use
of omic technologies is a promising tool and arena for further
improvement in the modernization of TCM.
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